Abstract

Autologous haematopoietic stem cell transplantation (AHSCT) is a vital therapeutic option for patients with highly active multiple sclerosis (MS). Rates of remission suggest AHSCT is the most effective form of immunotherapy in controlling the disease. Despite an evolving understanding of the biology of immune reconstitution following AHSCT, the mechanism by which AHSCT enables sustained disease remission beyond the period of lymphopenia remains to be elucidated. Auto-reactive T cells are considered central to MS pathogenesis. Here, we analyse T cell reconstitution for 36 months following AHSCT in a cohort of highly active MS patients. Through longitudinal analysis of sorted naïve and memory T cell clones, we establish that AHSCT induces profound changes in the dominant T cell landscape of both CD4+ and CD8+ memory T cell clones. Lymphopenia induced homeostatic proliferation is followed by clonal attrition; with only 19% of dominant CD4 (p <0.025) and 13% of dominant CD8 (p <0.005) clones from the pre-transplant repertoire detected at 36 months. Recovery of a thymically-derived CD4 naïve T cell repertoire occurs at 12 months and is ongoing at 36 months, however diversity of the naïve populations is not increased from baseline suggesting the principal mechanism of durable remission from MS after AHSCT relates to depletion of putative auto-reactive clones. In a cohort of MS patients expressing the MS risk allele HLA DRB1*15:01, public clones are probed as potential biomarkers of disease. AHSCT appears to induce sustained periods of disease remission with dynamic changes in the clonal T cell repertoire out to 36 months post-transplant.

Highlights

  • Multiple sclerosis (MS) is an inflammatory condition of the central nervous system (CNS) that is presumed to be mediated by an aberrant adaptive immune response [1]

  • Immune reconstitution analysis with multicolour flow cytometry was assessed in 19 relapsing-remitting multiple sclerosis (MS) patients for 24 months following Autologous haematopoietic stem cell transplantation (AHSCT), with a further analysis on 13 of the cohort undertaken at 36 months

  • AHSCT is administered in MS as a highly efficacious immune reconstitution treatment in autoimmune disease [63, 64], with therapeutic effects extending beyond the period of lymphopenia [65]

Read more

Summary

Introduction

Multiple sclerosis (MS) is an inflammatory condition of the central nervous system (CNS) that is presumed to be mediated by an aberrant adaptive immune response [1]. A paradigm shift in MS treatment, in favor of earlier high-efficacy therapy [7,8,9], along with increased recognition of the complications of long-term immune suppression in MS [10, 11] has led to interest in immunoablative therapies [7], including autologous haematopoietic stem cell transplantation (AHSCT). AHSCT is associated with periods of disease-free remission extending well beyond the period of immune reconstitution (IR) [12]. The future development of targeted IR therapies that lack the toxicity of chemotherapy necessitates an improved understanding of disease pathogenesis

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call